Coya Therapeutics, Inc. (COYA)
Oxford Ledge is still expanding full research coverage of COYA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Coya Therapeutics develops immunotherapies targeting regulatory T cell dysfunction for serious diseases including neurodegeneration and autoimmune conditions.
SEC filings
- 8-K Shareholder vote results 2026-06-25
- DEF 14A Proxy statement for shareholder vote 2026-05-13
- 8-K Entry into material agreement; Financial statements and exhibits 2026-05-12
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 8-K Results of operations / financial condition; Other material event; Financial statements and exhibits 2026-05-12
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for COYA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open COYA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.